Tun daga Disamba 2019, COVID-19 da ke haifar da Cutar Cutar Cutar Cutar Cutar Kwalara (SARS) ta bazu a duniya.Kwayar cutar da ke haifar da COVID-19 ita ce SARS-COV-2, mai ɗabi'a ɗaya da kwayar cutar RNA na dangin coronaviruses.β coronaviruses suna da siffa mai siffar zobe ko oval, 60-120 nm a diamita, kuma sau da yawa pleomorphic.Domin ambulan kwayar cutar tana da siffa mai dunkulewa wacce za ta iya zuwa kowane bangare kuma tana kama da corolla, ana kiranta coronavirus.Yana da capsule, kuma S (protein Spike), M (protein Membrane), M (protein matrix) da E (protein envelope) ana rarraba akan capsule.Ambulan ya ƙunshi haɗin RNA zuwa N ( furotin Nucleocapsid).S protein naSARS-COV-2ya ƙunshi sassan S1 da S2.Yankin mai karɓar mai karɓa (RBD) na S1 subunit yana haifar da kamuwa da cuta ta SARS-COV-2 ta hanyar ɗaure zuwa angiotensin mai canza enzyme 2 (ACE2) akan saman tantanin halitta.
Sars-cov-2 na iya yaɗuwa daga mutum zuwa mutum kuma yana iya yaɗuwa fiye da sarS-COV, wanda ya fito a cikin 2003. Yawanci yana ɗaukar ta ta hanyar ɗigon numfashi da kuma kusancin ɗan adam, kuma ana iya yada ta ta hanyar iska idan akwai a cikin muhalli. tare da kyakkyawan iska na dogon lokaci.Gabaɗaya mutane suna da saurin kamuwa da cuta, kuma lokacin shiryawa shine kwanaki 1 zuwa 14, galibi kwanaki 3 zuwa 3.Bayan kamuwa da cuta tare da novel coronavirus, ƙananan lokuta na COVID-19 za su haifar da alamun zazzabi da bushewar tari.COVID-19 yana da saurin yaduwa kuma yana yaduwa sosai a cikin matakan asymptomatic na kamuwa da cuta.Kwayar cutar Sars-cov-2 na iya haifar da zazzabi, bushewar tari, gajiya da sauran alamomi.Marasa lafiya masu tsanani sukan haifar da dyspnea da / ko hypoxemia 1 mako bayan farawa, kuma marasa lafiya masu tsanani na iya haifar da ciwo mai tsanani na numfashi, coagulopathy da gazawar gabobin jiki da yawa.
Saboda sarS-COV-2 yana da saurin yaduwa kuma yana kashe mutane, sauri, daidai kuma hanyoyin bincike masu dacewa don gano SARS-COV-2 da keɓe masu kamuwa da cuta (ciki har da masu cutar asymptomatic) sune mabuɗin gano tushen kamuwa da cuta, toshe hanyoyin yada cutar da hanawa da kuma shawo kan cutar.
POCT, wanda kuma aka sani da fasahar gano gefen gado ko fasaha na gano ainihin lokaci, wata nau'in hanyar ganowa ce da ake aiwatarwa a wurin yin samfur kuma tana iya samun sakamakon ganowa cikin sauri ta amfani da na'urori masu ɗaukar hoto.Dangane da gano ƙwayoyin cuta, POCT yana da fa'idodin saurin ganowa da sauri kuma babu ƙuntatawar rukunin yanar gizo idan aka kwatanta da hanyoyin gano al'ada.POCT ba wai kawai zai iya hanzarta gano COVID-19 ba, har ma ya guji hulɗa tsakanin ma'aikatan ganowa da marasa lafiya da rage haɗarin kamuwa da cuta.A halin yanzu,Gwajin COVID-19Shafukan da ke China galibi asibitoci ne da cibiyoyin gwaji na ɓangare na uku, kuma ma’aikatan gwajin suna buƙatar ɗaukar samfuri kai tsaye a gaban mutanen da za a gwada.Duk da matakan kariya, yin samfur kai tsaye daga majiyyaci yana ƙara haɗarin kamuwa da cuta ga mutumin da ya gwada ta.Sabili da haka, kamfaninmu ya ƙirƙira kayan aiki na musamman don mutane su yi samfura a gida, wanda ke da fa'idodin ganowa cikin sauri, aiki mai sauƙi, da ganowa a gida, tasha da sauran wurare ba tare da yanayin kariyar biosafety ba.
Babban fasahar da ake amfani da ita ita ce fasahar immunochromatography, wacce aka fi sani da Lateral Flow assay (LFA), wacce hanya ce mai saurin ganowa ta hanyar aikin capillary.A matsayin ingantacciyar fasahar ganowa cikin sauri, tana da aiki mai sauƙi, ɗan gajeren lokacin amsawa da tabbataccen sakamako.Wakilin daya shine colloidal gold immunochromatography paper (GLFA), wanda gabaɗaya ya haɗa da samfurin kushin, bond pad, fim ɗin nitrocellulose (NC) da kushin sha ruwa, da dai sauransu. An kafa kushin bond tare da antibody modified zinariya nanoparticles (AuNPs), da NC an gyara fim ɗin tare da kama antibody.Bayan an ƙara samfurin a cikin kushin samfurin, yana gudana ta hanyar haɗin gwiwa da fim ɗin NC a jere a ƙarƙashin aikin capillary, kuma a ƙarshe ya kai ga kushin abin sha.Lokacin da samfurin ya gudana ta cikin kushin dauri, abin da za a auna a cikin samfurin zai ɗaure tare da alamar rigakafin ƙwayar cuta;Lokacin da samfurin ya gudana ta cikin membrane na NC, samfurin da za a gwada an kama shi kuma an gyara shi ta hanyar antibody da aka kama, kuma jajayen bandeji sun bayyana a kan membrane na NC saboda tarin nanoparticles na zinariya.Ana iya samun saurin gano ingancin SARS-COV-2 ta hanyar lura da jajayen makada a wurin ganowa.Kit ɗin wannan hanyar yana da sauƙin kasuwanci da daidaitacce, mai sauƙin aiki da sauri don amsawa.Ya dace don tantance yawan jama'a kuma ana amfani da shi sosai wajen gano sabon coronavirus.
Novel coronavirus cututtukababban kalubale ne da ke fuskantar duniya.Gaggawa ganewar asali da magani akan lokaci shine mabuɗin cin nasara a yaƙin.A cikin fuskantar yawan kamuwa da cuta da kuma yawan mutanen da suka kamu da cutar, yana da matukar muhimmanci a samar da ingantattun na'urorin ganowa cikin sauri.An sani cewa a cikin samfuran da aka saba amfani da su, ruwan lavage na alveolar yana da mafi girman ƙimar inganci tsakanin swabs na pharyngeal, miya, sputum da ruwan lavage na alveolar.A halin yanzu, gwajin da aka fi sani da shi shine ɗaukar samfura daga waɗanda ake zargin masu ciwon makogwaro daga saman pharynx, ba ƙananan hanyoyin numfashi ba, inda kwayar cutar za ta iya shiga cikin sauƙi.Hakanan ana iya gano kwayar cutar a cikin jini, fitsari, da kuma najasa, amma ba ita ce wurin da ake kamuwa da ita ba, don haka adadin kwayar cutar ba ta da yawa kuma ba za a iya amfani da shi azaman tushen ganowa ba.Bugu da ƙari, yayin da RNA ba ta da ƙarfi sosai kuma mai sauƙi don ƙasƙanta, magani mai dacewa da kuma fitar da samfurori bayan tattarawa suma dalilai ne.
1. Chan JF, Kok KH, Zhu Z, et al.Halayen genomic na 2019 novel ɗan adam-mai cutar coronavirus keɓe daga majiyyaci mai cutar huhu bayan ya ziyarci Wuhan［J］.Kwayoyin cuta masu tasowa, 2020, 9 ( 1): 221-236.
2. Hu B., Guo H., Zhou P., Shi ZL, Nat.Rev. Microbiol., 2021, 19, 141-154
3］ Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X. Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Z., Ma J., Liu WJ, Wang D.,Xu W., Holmes EC, Gao GF, Wu G., Chen W., Shi W., Tan W., Lancet, 2020, 395, 565-574
Lokacin aikawa: Mayu-20-2022